Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zapnometinib - Atriva Therapeutics

Next Previous
X
Search
Drug Profile

Zapnometinib - Atriva Therapeutics

Alternative Names: ATR-002; PD01842649

Latest Information Update: 11 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Muenster
  • Developer Atriva Therapeutics
  • Class Amines; Antivirals; Benzoic acids; Chlorobenzenes; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hantavirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections
  • Preclinical Hantavirus infections
  • No development reported Influenza virus infections

Most Recent Events

  • 06 Jun 2024 Atriva Therapeutics has patent protection for zapnometinib in USA
  • 04 Oct 2023 Efficacy and adverse events data from the phase IIa RESPIRE trial in COVID-2019 infections released by Atriva Therapeutics
  • 20 Jul 2023 Atriva Therapeutics completes a phase I trial in Healthy volunteers in Germany (PO) (NCT05555823)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top